Variable | pSS-OA | pSS-nOA | p value1 | OR | p value2 |
---|---|---|---|---|---|
n = 186 | n = 182 | ||||
Female (n, %) | 172(92.5) | 166(91.2) | 0.659 | ||
Age (≥ 65 year) (n, %) | 71(38.2) | 41(22.5) | 0.001 | 1.965 | 0.009 |
Disease duration (year) M (IQR) | 5(2–10) | 3(1–10) | 0.034 | 1.023 | 0.112 |
Clinical manifestation (n, %) | |||||
Dry mouth | 164(88.2) | 150(82.4) | 0.119 | ||
Dry eye | 134(72.8) | 121(66.9) | 0.215 | ||
Mouth ulcers | 52(28.0) | 37(20.3) | 0.088 | ||
Dental caries and dentures | 114(61.3) | 102(56.0) | 0.308 | ||
Swollen parotid gland | 20(10.8) | 20(11.0) | 0.942 | ||
Rash | 34(18.3) | 45(24.7) | 0.133 | ||
Renault phenomenon | 22(11.8) | 32(17.6) | 0.119 | ||
Joint pain | 108(58.1) | 54(29.7) | < 0.001 | 3.382 | < 0.001 |
Fatigue | 35(18.8) | 43(23.6) | 0.260 | ||
ESSDAI score M (IQR) | 4(2–8) | 5(3–10) | 0.006 | 0.965 | 0.098 |
ESSDAI domains (n, %) | |||||
Constitutional | 1(0.5) | 1(0.5) | 1.000 | ||
Lymphadenopathy | 8(4.3) | 11(6.0) | 0.451 | ||
Glandular | 22(11.8) | 17(9.4) | 0.461 | ||
Articular | 24(12.9) | 17(9.4) | 0.279 | ||
Cutaneous | 5(2.7) | 13(7.1) | 0.048 | 0.359 | 0.057 |
Pulmonary | 35(18.8) | 42(23.5) | 0.278 | ||
Renal | 7(3.8) | 6(3.4) | 0.833 | ||
Muscular | 4(2.2) | 3(1.6) | 1.000 | ||
Peripheral nervous system | 6(3.2) | 11(6.0) | 0.199 | ||
Central nervous system | 0(0.0) | 1(0.5) | 0.495 | ||
Hematological | 109(58.6) | 123(67.6) | 0.075 | ||
Biological | 103(55.7) | 114(64.8) | 0.078 | ||
Laboratory data | |||||
Hemoglobin (g/L), x ± s | 119 ± 14.8 | 115 ± 18.8 | 0.030 | 1.005 | 0.515 |
A/G | 1.3 ± 0.3 | 1.2 ± 0.3 | 0.012 | 0.847 | 0.796 |
Globulin (g/L), x ± s | 31.8 ± 7.5 | 34.5 ± 11.0 | 0.008 | 0.958 | 0.128 |
Albumin (g/L), x ± s | 38.2 ± 6.0 | 37.1 ± 5.1 | 0.058 | ||
K+ (mmol/L), x ± s | 3.8 ± 0.3 | 3.7 ± 0.4 | 0.015 | 1.404 | 0.263 |
Uric acid (umol/L), M (IQR) | 276(234.7–328.3) | 261(218.0–317.0) | 0.030 | 1.002 | 0.104 |
TC (mmol/L), M (IQR) | 4.6(4.0–5.3) | 4.5(3.7–4.9) | 0.025 | 1.015 | 0.670 |
TG (mmol/L), M (IQR) | 1.3(0.9–1.7) | 1.3(0.9–1.4) | 0.287 | ||
HDL (mmol/L), M (IQR) | 1.2(1.0–1.4) | 1.2(0.9–1.3) | 0.064 | ||
FBG (mmol/L), x ± s | 5.0 ± 1.0 | 4.9 ± 1.0 | 0.537 | ||
C3 (g/L), x ± s | 1.0 ± 0.2 | 0.9 ± 0.2 | 0.256 | ||
C4 (g/L), x ± s | 0.2 ± 0.1 | 0.19 ± 0.1 | 0.004 | 4.213 | 0.430 |
ANA positive (n, %) | 113(61.1) | 131(72.0) | 0.027 | 0.676 | 0.120 |
Anti-SSA positive (n, %) | 107(57.8) | 123(67.6) | 0.054 | ||
Anti-SSB positive (n, %) | 48(25.9) | 53(29.1) | 0.497 | ||
Anti-CCP positive (n, %) | 5(3.1) | 4(2.8) | 0.868 | ||
Increased RF (n, %) | 38(22.9) | 45(28.3) | 0.265 | ||
IgA (g/L), x ± s | 2.9 ± 1.4 | 3.3 ± 2.9 | 0.049 | 0.894 | 0.060 |
IgM (g/L), x ± s | 1.4 ± 1.4 | 1.6 ± 2.2 | 0.444 | ||
IgG (g/L), x ± s | 15.5 ± 6.0 | 16.7 ± 7.2 | 0.035 | 1.029 | 0.357 |
IgG4 (g/L), x ± s | 0.6 ± 1.8 | 0.5 ± 0.8 | 0.696 | ||
Increased CRP (n, %) | 15(8.3) | 23(13.3) | 0.133 | ||
Increased ESR (n, %) | 51(28.3) | 60(36.1) | 0.121 | ||
Decreased 25-(OH)D (n, %) | 28(17.5) | 18(12.5) | 0.226 |